Christopher Harbison
Impact in
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Molecular Biology top 1%
- Genomics and Chromatin Dynamics
- Fungal and yeast genetics research
- Bioinformatics and Genomic Networks
- RNA Research and Splicing
Papers in
- Oncology 55
- Cancer Immunotherapy and Biomarkers 38
- Colorectal Cancer Treatments and Studies 24
- Peptidase Inhibition and Analysis 8
- Lung Cancer Research Studies 6
- CAR-T cell therapy research 5
-
- Lung Cancer Treatments and Mutations 26
- Gastric Cancer Management and Outcomes 10
- Co-authors
- Richard A. Young (5 shared papers)Tong Ihn Lee (3 shared papers)Nancy M. Hannett (4 shared papers)Julia Zeitlinger (4 shared papers)David K. Gifford (3 shared papers)Ezra G. Jennings (2 shared papers)Eric S. Lander (2 shared papers)Dmitry Pokholok (2 shared papers)
- Journals
- Journal of Clinical Oncology (27 papers)Annals of Oncology (8 papers)International Journal of Radiation Oncology*Biology*Physics (5 papers)European Journal of Cancer (3 papers)Cell (3 papers)
- Partner nations
- United StatesItalyGermany
In The Last Decade
Christopher Harbison
62 papers receiving 9.2k citations
Christopher Harbison's Hit Papers
Peers
Comparison fields: 5 of 139
- Oncology 4.1k
- Molecular Biology 5.0k
- Pulmonary and Respiratory Medicine 2.3k
- Immunology 1.2k
- Aging 97
Countries citing papers authored by Christopher Harbison
This map shows the geographic impact of Christopher Harbison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Harbison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Harbison more than expected).
Fields of papers citing papers by Christopher Harbison
This network shows the impact of papers produced by Christopher Harbison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Harbison. The network helps show where Christopher Harbison may publish in the future.
Co-authors
The 25 scholars most cited alongside Christopher Harbison, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 63 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Transcriptional regulatory code of a eukaryotic genome Hit paper breakdown → | 2004 | 1653 |
| 2 | Genome-wide Map of Nucleosome Acetylation and Methylation in Yeast Hit paper breakdown → | 2005 | 1098 |
| 3 | Remodeling of Yeast Genome Expression in Response to Environmental Changes Hit paper breakdown → | 2001 | 1082 |
| 4 | Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab Hit paper breakdown → | 2007 | 898 |
| 5 | Serial Regulation of Transcriptional Regulators in the Yeast Cell Cycle Hit paper breakdown → | 2001 | 503 |
| 6 | CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer Hit paper breakdown → | 2018 | 471 |
| 7 | Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab Hit paper breakdown → | 2019 | 409 |
| 8 | Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2016 | 394 |
| 9 | Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143 Hit paper breakdown → | 2017 | 362 |
| 10 | Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2016 | 350 |
| 11 | 2010 | 212 | |
| 12 | 2003 | 186 | |
| 13 | 2007 | 141 | |
| 14 | 2015 | 121 | |
| 15 | 2017 | 119 | |
| 16 | 2014 | 118 | |
| 17 | 2014 | 99 | |
| 18 | 2014 | 87 | |
| 19 | 2011 | 81 | |
| 20 | 2014 | 72 |
About Christopher Harbison
Christopher Harbison is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Surgery and Radiology, Nuclear Medicine and Imaging, having authored 63 papers that have together received 9.4k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (38 papers), Lung Cancer Treatments and Mutations (26 papers), Colorectal Cancer Treatments and Studies (24 papers), Gastric Cancer Management and Outcomes (10 papers), Peptidase Inhibition and Analysis (8 papers), Lung Cancer Research Studies (6 papers), Fungal and yeast genetics research (5 papers) and CAR-T cell therapy research (5 papers). The work is most often cited by research in Oncology (4.1k citations), Molecular Biology (5.0k citations), Pulmonary and Respiratory Medicine (2.3k citations), Immunology (1.2k citations) and Aging (97 citations). Christopher Harbison has collaborated with scholars based in United States, Italy and Germany. Frequent co-authors include Richard A. Young, Tong Ihn Lee, Nancy M. Hannett, Julia Zeitlinger, David K. Gifford, Ezra G. Jennings, Eric S. Lander, Dmitry Pokholok, Scott Gettinger and Nicola J. Rinaldi. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, International Journal of Radiation Oncology*Biology*Physics, European Journal of Cancer and Cell.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.